JP2017501848A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501848A5
JP2017501848A5 JP2016553757A JP2016553757A JP2017501848A5 JP 2017501848 A5 JP2017501848 A5 JP 2017501848A5 JP 2016553757 A JP2016553757 A JP 2016553757A JP 2016553757 A JP2016553757 A JP 2016553757A JP 2017501848 A5 JP2017501848 A5 JP 2017501848A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
humanized
synuclein
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016553757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501848A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/066141 external-priority patent/WO2015075635A2/en
Publication of JP2017501848A publication Critical patent/JP2017501848A/ja
Publication of JP2017501848A5 publication Critical patent/JP2017501848A5/ja
Pending legal-status Critical Current

Links

JP2016553757A 2013-11-19 2014-11-19 便秘症状からのレビー小体病の免疫療法のモニター Pending JP2017501848A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906372P 2013-11-19 2013-11-19
US61/906,372 2013-11-19
PCT/IB2014/066141 WO2015075635A2 (en) 2013-11-19 2014-11-19 Monitoring immunotherapy of lewy body disease from constipation symptoms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019171039A Division JP2020011978A (ja) 2013-11-19 2019-09-20 便秘症状からのレビー小体病の免疫療法のモニター

Publications (2)

Publication Number Publication Date
JP2017501848A JP2017501848A (ja) 2017-01-19
JP2017501848A5 true JP2017501848A5 (enExample) 2017-12-28

Family

ID=52000905

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553757A Pending JP2017501848A (ja) 2013-11-19 2014-11-19 便秘症状からのレビー小体病の免疫療法のモニター
JP2019171039A Pending JP2020011978A (ja) 2013-11-19 2019-09-20 便秘症状からのレビー小体病の免疫療法のモニター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019171039A Pending JP2020011978A (ja) 2013-11-19 2019-09-20 便秘症状からのレビー小体病の免疫療法のモニター

Country Status (4)

Country Link
US (1) US11191832B2 (enExample)
EP (1) EP3071974A2 (enExample)
JP (2) JP2017501848A (enExample)
WO (1) WO2015075635A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
EP3943942A1 (en) 2014-02-14 2022-01-26 betaSENSE GmbH Biosensor for conformation and secondary structure analysis
ES2834484T3 (es) 2016-11-21 2021-06-17 Univ Ruhr Bochum Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JP7075648B2 (ja) * 2017-07-05 2022-05-26 ディメンシア・フロント株式会社 脳機能疾病鑑別方法及び該方法を含むプログラムを実行するコンピュータプログラムプロダクト
AU2017434556B2 (en) * 2017-09-28 2024-11-14 F. Hoffmann-La Roche Ag Dosing regimes for treatment of synucleinopathies
SG11202004441XA (en) 2017-11-14 2020-06-29 Univ Osaka Cognitive impairment diagnostic apparatus and cognitive impairment diagnostic program
WO2019117685A2 (ko) * 2017-12-14 2019-06-20 에이비엘바이오 주식회사 항-igf1r 항체 및 그 용도
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
CN113966346A (zh) * 2019-06-14 2022-01-21 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
CR20220531A (es) * 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
EP4211162A4 (en) 2020-09-10 2025-04-30 Prothena Biosciences Limited TREATMENT OF PARKINSON'S DISEASE

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
CA2234685A1 (en) 1995-11-10 1997-05-15 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
NZ513144A (en) 1999-02-05 2003-05-30 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
DK1567652T3 (da) 2002-11-29 2007-11-26 Boehringer Ingelheim Pharma Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler
WO2005013889A2 (en) 2003-05-19 2005-02-17 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005011389A1 (en) * 2003-07-29 2005-02-10 Fra Production S.P.A. Machine for automatically presenting poultry to an operator entrusted with their tying
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
KR101235658B1 (ko) 2004-11-10 2013-02-21 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Cho 세포에 대한 세포 뱅킹 전략을 최적화하기 위한 유동 세포측정 분석의 용도
US8502016B1 (en) 2005-02-11 2013-08-06 Elan Pharmaceuticals, Inc. Genomic alpha synuclein transgenic animal
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US20120142902A1 (en) 2007-02-23 2012-06-07 The Regents Of The University Of California Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
PL2583978T3 (pl) * 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
EP2522729A1 (en) 2007-03-02 2012-11-14 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
FI3378535T3 (fi) 2011-10-28 2023-04-12 Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター

Similar Documents

Publication Publication Date Title
JP2017501848A5 (enExample)
JP2015505564A5 (enExample)
JP2017079785A5 (enExample)
JP2017149726A5 (enExample)
JP2015525798A5 (enExample)
JP2016530280A5 (enExample)
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
JP2015007098A5 (enExample)
PH12015501531A1 (en) Crenolanib for treating flt3 mutated proliferative disorders
JP2016512817A5 (enExample)
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
JP2016515628A5 (enExample)
JP2012102122A5 (enExample)
JP2016539125A5 (enExample)
JP2018530578A5 (enExample)
EA201790475A1 (ru) Способы лечения системной красной волчанки с использованием доменного антитела против cd28
JP2019532047A5 (enExample)
CA2916283C (en) Dosage regimen for madcam antagonists
JP2017533220A5 (enExample)
JP2016510343A5 (enExample)
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.
JP2018529661A5 (enExample)
JP2015522603A5 (enExample)
JP2016539122A5 (enExample)
JP2016522188A5 (enExample)